文献速递神经免疫

抗炎性改善病情治疗对继发进展型多发性硬化短期残疾进展的影响

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
PubMed 文献 · Neurology · 2017-08-09

该国际队列研究基于MSBase数据,采用倾向性评分匹配比较继发进展型多发性硬化(SPMS)患者中接受与未接受改善病情治疗者的短期残疾结局。匹配后共1378例(各689例),中位随访2.1年,结果显示6个月持续残疾进展风险无显著差异(HR 0.9,95%CI 0.7-1.1,p=0.27),次要终点亦无差异。结论认为现有改善病情药物对SPMS的复发无关残疾结局平均无实质影响。

要点

  • SPMS患者使用改善病情药物未显著降低6个月持续残疾进展风险。
  • 达到EDSS≥7、持续残疾改善及残疾负荷变化等次要终点均无显著差异。
  • 证据等级为Class IV,提示现有药物对SPMS短期残疾进展无益。

核心结论

  • 汇总分析显示,转为SPMS后使用现有改善病情药物平均对EDSS测量的复发无关残疾结局无实质影响,随访至4年。

研究设计与样本

  • 国际队列研究MSBase,纳入2381例SPMS患者,倾向性评分匹配后1378例(治疗组689例,未治疗组689例)。

主要发现

  • 6个月持续残疾进展风险无差异(HR 0.9,95%CI 0.7-1.1,p=0.27)。
  • 达到EDSS≥7风险无差异(HR 0.6,95%CI 0.4-1.1,p=0.10)。
  • 持续残疾改善无差异(HR 1.0,95%CI 0.8-1.3,p=0.79)。
  • 残疾负荷变化无差异(EDSS-时间曲线下面积β=-0.05,p=0.09)。
  • 中位配对删失随访2.1年(四分位1.2-3.8年),次要和敏感性分析证实结果。

临床怎么用

  • 对已转为SPMS的患者,不应期望现有改善病情药物能显著延缓EDSS测量的短期残疾进展。

局限性

  • 证据等级为Class IV,研究为观察性队列而非随机对照试验。
  • 随访时间有限,中位仅2.1年,最长分析至4年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple sclerosis (SPMS). METHODS: Using MSBase, an international cohort study, we previously validated a highly accurate definition of SPMS. Here, we identified patients in MSBase who were either untreated or treated with a disease-modifying drug when meeting this definition. Propensity score matching was used to select subpopulations with comparable baseline characteristics. Disability outcomes were compared in paired, pairwise-censored analyses adjusted for treatment persistence, visit density, and relapse rates. RESULTS: Of the 2,381 included patients, 1,378 patients were matchable (treated n = 689, untreated n = 689). Median pairwise-censored follow-up was 2.1 years (quartiles 1.2-3.8 years). No difference in the risk of 6-month sustained disability progression was observed between the groups (hazard ratio [HR] 0.9, 95% confidence interval [CI] 0.7-1.1, p = 0.27). We also did not find differences in any of the secondary endpoints: risk of reaching Expanded Disability Status Scale (EDSS) score ≥7 (HR 0.6, 95% CI 0.4-1.1, p = 0.10), sustained disability reduction (HR 1.0, 95% CI 0.8-1.3, p = 0.79), or change in disability burden (area under the EDSS-time curve, β = -0.05, p = 0.09). Secondary and sensitivity analyses confirmed the results. CONCLUSIONS: Our pooled analysis of the currently available disease-modifying agents used after conversion to SPMS suggests that, on average, these therapies have no substantial effect on relapse-unrelated disability outcomes measured by the EDSS up to 4 years. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with SPMS, disease-modifying treatment has no beneficial effect on short-term disability progression.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lorscheider J, Jokubaitis VG, Spelman T, et al. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology. 2017. PMID: 28794248. doi:10.1212/WNL.0000000000004330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。